Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $27.37 million for the quarter.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Trading Down 1.2 %

Shares of Stoke Therapeutics stock opened at $9.76 on Monday. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $17.58. The company has a market cap of $527.80 million, a price-to-earnings ratio of -4.65 and a beta of 1.09. The company's 50-day moving average price is $7.80 and its 200-day moving average price is $10.27.

Wall Street Analysts Forecast Growth

STOK has been the subject of several research reports. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Chardan Capital restated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.67.

Insider Buying and Selling

In related news, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company's stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by corporate insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.